» Articles » PMID: 29751762

HIV Latency Reversing Agents Act Through Tat Post Translational Modifications

Overview
Journal Retrovirology
Publisher Biomed Central
Specialty Microbiology
Date 2018 May 13
PMID 29751762
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Different classes of latency reversing agents (LRAs) are being evaluated to measure their effects in reactivating HIV replication from latently infected cells. A limited number of studies have demonstrated additive effects of LRAs with the viral protein Tat in initiating transcription, but less is known about how LRAs interact with Tat, particularly through basic residues that may be post-translationally modified to alter the behaviour of Tat for processive transcription and co-transcriptional RNA processing.

Results: Here we show that various lysine and arginine mutations reduce the capacity of Tat to induce both transcription and mRNA splicing. The lysine 28 and lysine 50 residues of Tat, or the acetylation and methylation modifications of these basic amino acids, were essential for Tat transcriptional control, and also for the proviral expression effects elicited by histone deacetylase inhibitors (HDACi) or the bromodomain inhibitor JQ1. We also found that JQ1 was the only LRA tested that could induce HIV mRNA splicing in the absence of Tat, or rescue splicing for Tat lysine mutants in a BRD4-dependent manner.

Conclusions: Our data provide evidence that Tat activities in both co-transcriptional RNA processing together with transcriptional initiation and processivity are crucial during reactivation of latent HIV infection. The HDACi and JQ1 LRAs act with Tat to increase transcription, but JQ1 also enables post-transcriptional mRNA splicing. Tat residues K28 and K50, or their modifications through acetylation or methylation, are critical for LRAs that function in conjunction with Tat.

Citing Articles

Comprehensive SUMO Proteomic Analyses Identify HIV Latency-Associated Proteins in Microglia.

Imbert F, Langford D Cells. 2025; 14(3).

PMID: 39937027 PMC: 11817477. DOI: 10.3390/cells14030235.


Novel Triazolopyridine-Based BRD4 Inhibitors as Potent HIV-1 Latency Reversing Agents.

Wang Y, Huang X, Sun H, Ma M, Yu H, Hu W ACS Med Chem Lett. 2024; 15(1):60-68.

PMID: 38229757 PMC: 10789119. DOI: 10.1021/acsmedchemlett.3c00373.


HibeRNAtion: HIV-1 RNA Metabolism and Viral Latency.

Crespo R, Rao S, Mahmoudi T Front Cell Infect Microbiol. 2022; 12:855092.

PMID: 35774399 PMC: 9237370. DOI: 10.3389/fcimb.2022.855092.


Detection of Chimeric Cellular: HIV mRNAs Generated Through Aberrant Splicing in HIV-1 Latently Infected Resting CD4+ T Cells.

Lee M, Khoury G, Olshansky M, Sonza S, Carter G, McMahon J Front Cell Infect Microbiol. 2022; 12:855290.

PMID: 35573784 PMC: 9096486. DOI: 10.3389/fcimb.2022.855290.


HIV-1 Tat endocytosis and retention in endolysosomes affects HIV-1 Tat-induced LTR transactivation in astrocytes.

Khan N, Halcrow P, Afghah Z, Baral A, Geiger J, Chen X FASEB J. 2022; 36(3):e22184.

PMID: 35113458 PMC: 9627655. DOI: 10.1096/fj.202101722R.


References
1.
Anderson J, Johnson A, Howard J, Purcell D . Both linear and discontinuous ribosome scanning are used for translation initiation from bicistronic human immunodeficiency virus type 1 env mRNAs. J Virol. 2007; 81(9):4664-76. PMC: 1900145. DOI: 10.1128/JVI.01028-06. View

2.
Bartholomeeusen K, Xiang Y, Fujinaga K, Peterlin B . Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein. J Biol Chem. 2012; 287(43):36609-16. PMC: 3476326. DOI: 10.1074/jbc.M112.410746. View

3.
Banerjee C, Archin N, Michaels D, Belkina A, Denis G, Bradner J . BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol. 2012; 92(6):1147-54. PMC: 3501896. DOI: 10.1189/jlb.0312165. View

4.
Kuhn A, van Santen M, Schwienhorst A, Urlaub H, Luhrmann R . Stalling of spliceosome assembly at distinct stages by small-molecule inhibitors of protein acetylation and deacetylation. RNA. 2008; 15(1):153-75. PMC: 2612777. DOI: 10.1261/rna.1332609. View

5.
Boehm D, Calvanese V, Dar R, Xing S, Schroeder S, Martins L . BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle. 2012; 12(3):452-62. PMC: 3587446. DOI: 10.4161/cc.23309. View